Skip to main content

Lu-177-DOTATATE

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

  • RegistryNCT04086485
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionInoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
  • SponsorNational Cancer Institute (NCI)
How Lu-177-DOTATATE worksNCT040864851 min

What the film says

Read the transcript

This trial is for inoperable neuroendocrine tumors of the pancreas or intestine that have somatostatin receptors on the cells, in adults.

The idea: combine two drugs. Lutathera is given by infusion every 8 weeks for 4 cycles, with olaparib, a PARP inhibitor that blocks repair of DNA breaks. Part one raises the olaparib dose step by step. Part two asks whether the combination shrinks tumors.

The study plans 56 patients. At the National Institutes of Health Clinical Center in Bethesda, Frank Lin leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04086485

    Neuroendocrine tumors of pancreas or intestine, not curable by surgery, with somatostatin receptors, adults; Lutathera by infusion every 8 weeks for 4 cycles with olaparib; Olaparib is a PARP inhibitor that blocks repair of DNA breaks; Part one raises the olaparib dose step by step (+3 more lines)

The drug

What is being tested.

Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations

Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration

Background: * Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. * While the treatment of localized NETs is surgical resection, a variety of therapeutic options are available for patients with advanced NETs.

The study

How the trial runs.

Background: A neuroendocrine tumor is a rare type of tumor. It comes from body cells called neuroendocrine cells. Sometimes, these tumors develop in the gastrointestinal tract and pancreas. Researchers want to find out if a combination of drugs can shrink these tumors. Objective: To learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lutathera and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink.

Eligibility: Adults 18 and older who have a neuroendocrine tumor in the pancreas or intestine that cannot be cured by surgery and has somatostatin receptors on the cells. Design: Eligible participants will get Lutathera through an intravenous (IV) infusion every 8 weeks for 4 cycles. One cycle is 8 weeks. Each cycle includes a follow-up visit at week 4. For the IV, a small plastic tube is put into an arm vein.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Clinical diagnosis of GEP-NET disease, histologically consistent with neuroendocrine tumor.
  • Inoperable disease (metastatic, non-candidate for surgery with curative intent, locally advanced into vessels or other critical structures, etc.)
  • NOTE: Presence of at least one non-irradiated index lesion (Phase II only).
  • Patients on somatostatin analogue therapy (e.g., but not only limited to sandostatin or lanreotide therapy) must have initiated and been on a consistent dose of therapy for at least 3 months prior to study enrollment.
  • Patients on short-term octreotide must have dose held for 24 hours without octreotide because this is necessary for study Lu-177-DOTATATE therapy.
  • Age >=18 years. Because no dosing or adverse event data are currently available on the use of Lu-177-DOTATATE in combination with olaparib in patients <18 years of age, children are excluded from this study, but may be eligible for future pediatric trials.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.